HMG CoA reductase inhibitors and renoprotection: the weight of the evidence. - Wikidata - wikimedia - TriplyDB

HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.

HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.

http://www.wikidata.org/entity/Q37362681

about

Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs).Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options.The administration of pitavastatin augments creatinine clearance associated with reduction in oxidative stress parameters: acute and early effects.

P2860

Q35157953-971A36B6-1364-45DB-B51E-DDF683BF4B67 Q38087529-0027E428-C9CB-4241-8417-662BE7E014E2 Q43746740-4DDFD141-C216-4319-9395-0BA028B0B50C

P2860

HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.

http://www.wikidata.org/entity/Q37362681

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.

@en

HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.

@nl

type

label

HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.

@en

HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.

@nl

prefLabel

HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.

@en

HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.

@nl

P1433

Q37362681-A021F47D-5557-408E-BF54-31BDA5747B71

P1476

Q37362681-7CF43DA6-8E13-4F10-9042-3C81A146C750

P2093

Q37362681-2EC1E62B-572B-401A-9F3E-BF98E1AAE6E0

Q37362681-3FFAB60A-A751-44EC-8290-E2341AFC115A

Q37362681-AFB2CBE4-45BB-4393-A4C6-CDD57C060FC1

Q37362681-D592DF6C-E223-4A59-9465-AB2FA8D53151

Q37362681-E81A9F92-E5EB-4965-8A1B-7966ADD65548

P2860

Q37362681-071E0F4D-5810-458C-8EBA-CC94AE4EDC0D

Q37362681-13D5448D-44F0-44C9-A1D2-1E97F678C244

Q37362681-173F69F7-0249-4087-A161-E4578BC915FB

Q37362681-265964E9-F567-4B17-844B-BA08A4AB45C2

Q37362681-2C3E783C-E124-478A-A152-44ED8373651A

Q37362681-3236032E-D6F6-40A5-B605-21A49DD6F1D6

Q37362681-41559CF4-13C5-407F-805C-9E72D0D96B94

Q37362681-42EC12F1-8A45-4A28-8FC5-79187B765004

Q37362681-4DA35299-A457-40E7-8809-7C881EEEDCEE

Q37362681-58F6570F-9D27-483F-ABB2-4648A6D1288D

P304

Q37362681-C5B8AB23-0EC4-4A58-9D88-F15D15959EA3

P31

Q37362681-7668EE3E-9CE5-4B4F-AA71-FA4EECA6A01F

P356

Q37362681-749FCBD5-7CD4-456D-9326-75E4C786EE51

P433

Q37362681-EA89AEF3-89EE-4CF0-BA38-F64EB315CDAF

P478

Q37362681-C7E05777-8967-4473-9120-B03E08B0CA43

P577

Q37362681-CF9607BA-B2B9-413E-AB0A-39B6200928B0

P698

Q37362681-6BFE9BAD-C543-44EC-9AA8-A9DDED01194F

P356

1753944707082714

P1433

Therapeutic advances in cardiovascular disease

P1476

HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.

@en

P2093

Adam Whaley Connell

http://www.w3.org/2001/XMLSchema#string

Ganesh Athappan

http://www.w3.org/2001/XMLSchema#string

Georges Saab

http://www.w3.org/2001/XMLSchema#string

James R Sowers

http://www.w3.org/2001/XMLSchema#string

L Romayne Kurukulasuriya

http://www.w3.org/2001/XMLSchema#string

P2860

Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma

HMG-CoA reductase inhibition aborts functional differentiation and triggers apoptosis in cultured primary human monocytes: a potential mechanism of statin-mediated vasculoprotection

Premature cardiovascular disease in chronic renal failure.

Transcription factor-kappa B (NF-kappa B) and renal disease.

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

Endothelium-dependent effects of statins.

Why do we need a statin trial in hemodialysis patients?

Study of Heart and Renal Protection (SHARP).

The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.

Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress.

P304

49-59

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1753944707082714

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2007-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19124395

http://www.w3.org/2001/XMLSchema#string